Developer docs
API playgroundTry for free, no card

Search company profiles

Kalohexis

Full company profile

uuid00qav9t

Namestring
Kalohexis
Legal namestring
Kalohexis, LLC
Websiteurl
kalohexis.com
Company typeenum
Private
Founded yearint
2026
Descriptiontext

Kalohexis is a clinical-stage biotechnology company developing a proprietary pipeline of therapeutic peptides designed to drug central melanocortin-3 and melanocortin-4 (MC3R/MC4R) receptors to treat metabolic disorders. The company was spun out of Endevica Bio in March 2026 and is headquartered in Northbrook, Illinois, operating as Kalohexis, LLC (Delaware). Its lead asset 710GO is an oral dual MC3R/MC4R agonist currently in a Phase 1 clinical trial in Australia enrolling approximately 100 healthy overweight or obese volunteers; preclinical data report 11.7–11.8% body weight loss in nonhuman primates over 13–15 weeks with lean-mass preservation, limited rebound after treatment cessation, and no gastrointestinal adverse events. Its second lead asset, mifomelatide (TCMCB07), is a dual MC3R/MC4R antagonist in a Phase 2 trial (Paradox, NCT06937177) for cancer cachexia in patients with advanced colorectal cancer, an indication with no FDA-approved therapies in the US. The pipeline additionally includes preclinical MC4R-selective and MC3R-selective agonist candidates targeting type 2 diabetes, MASH, opioid use disorder, sarcopenia, PCOS, and related metabolic indications.

The company's technology relies on proprietary peptide design optimized for blood-brain barrier penetration and central receptor engagement, developed over more than a decade by the Endevica Bio scientific team. Underlying differentiation is the dual-receptor mechanism, which the company positions as overcoming the safety and efficacy limitations of earlier MC4R-selective approaches and of GLP-1-based obesity therapies (poor tolerability, lean-mass loss, weight rebound). Development activities are conducted through clinical research sites with CRO support, including a WuXi Clinical partnership for the Phase 2 Paradox trial.

Kalohexis operates a pre-revenue pharmaceutical development model. Revenue generation is contingent on successful clinical advancement, regulatory approval, and commercialization of pipeline assets; pricing for any approved therapeutics would be set at the time of market launch. Go-to-market is the traditional biotech pharmaceutical pathway (wholesalers, hospital/specialty pharmacies, direct provider ordering) upon commercialization, and near-term commercial focus is on scientific publication, conference presentation (ENDO, AACR), and corporate communications to build credibility with investors and the medical community. Kalohexis shares leadership with Endevica Bio (CEO Russell Potterfield, CMSO Dr. Daniel Marks) and has added CFO Tony Mitchell and Director of Corporate Strategy Xuan Hui in 2026 to support capital formation and pipeline expansion.

Short descriptiontext

Kalohexis is a clinical-stage biotechnology company developing proprietary peptide therapeutics targeting central MC3R/MC4R receptors for metabolic disorders, with lead programs in Phase 1 for obesity (710GO) and Phase 2 for cancer cachexia (mifomelatide). It is a pre-revenue spin-out of Endevica Bio headquartered in Northbrook, Illinois.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNorthbrook, United States
HQ citystring
Northbrook
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide therapeutics, melanocortin receptor agonists, obesity drug development, cancer cachexia treatment, metabolic disease biotech
Industry2 codes
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
Product category
Metabolic Disease Peptide Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development
TypeSubscription Recurring
Description

As a clinical-stage biotechnology company, Kalohexis is in the pre-revenue stage of development. The company is advancing two lead therapeutic candidates through clinical trials: 710GO for obesity (Phase 1) and mifomelatide for cancer cachexia (Phase 2). Revenue generation is contingent on successful clinical development, regulatory approval, and commercialization of these pipeline assets.

kalohexis.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Kalohexis is a clinical-stage biotechnology company developing a proprietary pipeline of therapeutic peptides that target the central melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) to treat metabolic disorders. Its lead clinical assets are 710GO, an oral dual MC3R/MC4R agonist for general obesity currently in Phase 1 testing in Australia, and mifomelatide (TCMCB07), a dual MC3R/MC4R antagonist for cancer cachexia currently in Phase 2 (Paradox trial, NCT06937177) for advanced colorectal cancer. The pipeline also includes preclinical MC4R-selective and MC3R-selective agonist programs targeting additional metabolic indications such as type 2 diabetes, MASH, opioid use disorder, sarcopenia, and polycystic ovary syndrome.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 11.7% body weight loss at 13 weeks in diet-induced obese nonhuman primates treated with 710GO
+5 more records
Product overview1 text field

Kalohexis is a clinical-stage biotechnology company developing a proprietary pipeline of therapeutic peptides designed to safely and effectively modulate central melanocortin-3 and -4 receptors (MC3R/MC4R) to treat metabolic disorders. The company's portfolio consists of two lead clinical-stage assets: 710GO, an oral dual MC3R/MC4R agonist for general obesity currently in Phase 1 trials, and mifomelatide (TCMCB07), a dual MC3R/MC4R antagonist for cancer cachexia in Phase 2 development. Beyond these lead programs, the pipeline includes first-in-class MC4R-selective and MC3R-selective agonists targeting additional metabolic indications such as type 2 diabetes, metabolic dysfunction-associated steatohepatitis, opioid use disorder, sarcopenia, and polycystic ovary syndrome. The company operates as a single product/platform entity focused entirely on melanocortin-based peptide therapeutics.

Product and service4 records
1710GO
CategoryObesity therapeutics (lead clinical asset)
Description

An oral dual MC3R/MC4R agonist therapeutic peptide being evaluated in Phase 1 clinical trials as a next-generation treatment for general obesity. It activates the central melanocortin system to change the metabolic set point, inducing healthier and more durable weight loss while preserving lean mass and avoiding common side effects of GLP-1 agonists.

2Mifomelatide (TCMCB07 / B07)
CategoryCancer cachexia therapeutics (lead clinical asset)
Description

A dual MC3R/MC4R antagonist therapeutic peptide being evaluated in Phase 2 clinical trials (Paradox trial, NCT06937177) to prevent and treat cancer cachexia in patients with advanced cancers. It targets the central melanocortin system to prevent unintentional weight loss and preserve muscle and fat mass during chemotherapy.

3MC4R-Selective Agonists (pipeline program)
CategoryPreclinical pipeline programs
Description

First-in-class MC4R-selective agonist candidates in preclinical development with potential to address multiple metabolic indications including type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), opioid use disorder, sarcopenia, polycystic ovary syndrome (PCOS), muscle retention adjuvant, and menopausal weight maintenance.

4MC3R-Selective Agonists (pipeline program)
CategoryPreclinical pipeline programs
Description

First-in-class MC3R-selective agonist candidates in preclinical development targeting additional metabolic disorders with significant unmet medical needs.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-30
Description

WuXi Clinical is partnered with Kalohexis (formerly Endevica Bio) for the Phase 2 clinical trial of mifomelatide (TCMCB07) for cancer cachexia. The trial includes 20 sites and 100 patients diagnosed with stage 4 metastatic colorectal cancer. WuXi Clinical provides clinical research services supporting the trial administration and patient enrollment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-21
Description

Endevica Bio spun out Kalohexis in March 2026 to advance clinical development of the melanocortin-based therapeutic pipeline. Endevica Bio, a world leader in discovery of first-in-class synthetic peptidomimetics, had developed the core technology and pipeline assets over more than a decade. Kalohexis now administers ongoing clinical trials including the Phase 2 Paradox trial (NCT06937177) initiated by Endevica Bio. Kalohexis leadership includes Endevica Bio executives.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kalohexis

Metabolic Disease Peptide Therapeuticskalohexis.com

Kalohexis is a clinical-stage biotechnology company developing proprietary peptide therapeutics targeting central MC3R/MC4R receptors for metabolic disorders, with lead programs in Phase 1 for obesity (710GO) and Phase 2 for cancer cachexia (mifomelatide). It is a pre-revenue spin-out of Endevica Bio headquartered in Northbrook, Illinois.

What Kalohexis does

Kalohexis is a clinical-stage biotechnology company developing a proprietary pipeline of therapeutic peptides designed to drug central melanocortin-3 and melanocortin-4 (MC3R/MC4R) receptors to treat metabolic disorders. The company was spun out of Endevica Bio in March 2026 and is headquartered in Northbrook, Illinois, operating as Kalohexis, LLC (Delaware). Its lead asset 710GO is an oral dual MC3R/MC4R agonist currently in a Phase 1 clinical trial in Australia enrolling approximately 100 healthy overweight or obese volunteers; preclinical data report 11.7–11.8% body weight loss in nonhuman primates over 13–15 weeks with lean-mass preservation, limited rebound after treatment cessation, and no gastrointestinal adverse events. Its second lead asset, mifomelatide (TCMCB07), is a dual MC3R/MC4R antagonist in a Phase 2 trial (Paradox, NCT06937177) for cancer cachexia in patients with advanced colorectal cancer, an indication with no FDA-approved therapies in the US. The pipeline additionally includes preclinical MC4R-selective and MC3R-selective agonist candidates targeting type 2 diabetes, MASH, opioid use disorder, sarcopenia, PCOS, and related metabolic indications.

The company's technology relies on proprietary peptide design optimized for blood-brain barrier penetration and central receptor engagement, developed over more than a decade by the Endevica Bio scientific team. Underlying differentiation is the dual-receptor mechanism, which the company positions as overcoming the safety and efficacy limitations of earlier MC4R-selective approaches and of GLP-1-based obesity therapies (poor tolerability, lean-mass loss, weight rebound). Development activities are conducted through clinical research sites with CRO support, including a WuXi Clinical partnership for the Phase 2 Paradox trial.

Kalohexis operates a pre-revenue pharmaceutical development model. Revenue generation is contingent on successful clinical advancement, regulatory approval, and commercialization of pipeline assets; pricing for any approved therapeutics would be set at the time of market launch. Go-to-market is the traditional biotech pharmaceutical pathway (wholesalers, hospital/specialty pharmacies, direct provider ordering) upon commercialization, and near-term commercial focus is on scientific publication, conference presentation (ENDO, AACR), and corporate communications to build credibility with investors and the medical community. Kalohexis shares leadership with Endevica Bio (CEO Russell Potterfield, CMSO Dr. Daniel Marks) and has added CFO Tony Mitchell and Director of Corporate Strategy Xuan Hui in 2026 to support capital formation and pipeline expansion.

Kalohexis firmographics

Firmographics
Name
Kalohexis
Legal name
Kalohexis, LLC
Website
https://kalohexis.com
Company type
Private
Founded year
2026
Operating status
Operating
Headcount range
1–10 employees
Short description
Kalohexis is a clinical-stage biotechnology company developing proprietary peptide therapeutics targeting central MC3R/MC4R receptors for metabolic disorders, with lead programs in Phase 1 for obesity (710GO) and Phase 2 for cancer cachexia (mifomelatide). It is a pre-revenue spin-out of Endevica Bio headquartered in Northbrook, Illinois.
Ownership category
akta.pro rank

Kalohexis industry classification

Industry
Product category
Metabolic Disease Peptide Therapeutics
akta.pro industry
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals

Keywords

  • Peptide therapeutics
  • Melanocortin receptor agonists
  • Obesity drug development
  • Cancer cachexia treatment
  • Metabolic disease biotech

Where Kalohexis is headquartered

Location

Headquarters

HQ city
Northbrook
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kalohexis business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Development: As a clinical-stage biotechnology company, Kalohexis is in the pre-revenue stage of development. The company is advancing two lead therapeutic candidates through clinical trials: 710GO for obesity (Phase 1) and mifomelatide for cancer cachexia (Phase 2). Revenue generation is contingent on successful clinical development, regulatory approval, and commercialization of these pipeline assets.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Kalohexis product offering

Product offering

Core offering

Kalohexis is a clinical-stage biotechnology company developing a proprietary pipeline of therapeutic peptides that target the central melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) to treat metabolic disorders. Its lead clinical assets are 710GO, an oral dual MC3R/MC4R agonist for general obesity currently in Phase 1 testing in Australia, and mifomelatide (TCMCB07), a dual MC3R/MC4R antagonist for cancer cachexia currently in Phase 2 (Paradox trial, NCT06937177) for advanced colorectal cancer. The pipeline also includes preclinical MC4R-selective and MC3R-selective agonist programs targeting additional metabolic indications such as type 2 diabetes, MASH, opioid use disorder, sarcopenia, and polycystic ovary syndrome.

Product overview

Kalohexis is a clinical-stage biotechnology company developing a proprietary pipeline of therapeutic peptides designed to safely and effectively modulate central melanocortin-3 and -4 receptors (MC3R/MC4R) to treat metabolic disorders. The company's portfolio consists of two lead clinical-stage assets: 710GO, an oral dual MC3R/MC4R agonist for general obesity currently in Phase 1 trials, and mifomelatide (TCMCB07), a dual MC3R/MC4R antagonist for cancer cachexia in Phase 2 development. Beyond these lead programs, the pipeline includes first-in-class MC4R-selective and MC3R-selective agonists targeting additional metabolic indications such as type 2 diabetes, metabolic dysfunction-associated steatohepatitis, opioid use disorder, sarcopenia, and polycystic ovary syndrome. The company operates as a single product/platform entity focused entirely on melanocortin-based peptide therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

  • 710GO An oral dual MC3R/MC4R agonist therapeutic peptide being evaluated in Phase 1 clinical trials as a next-generation treatment for general obesity. It activates the central melanocortin system to change the metabolic set point, inducing healthier and more durable weight loss while preserving lean mass and avoiding common side effects of GLP-1 agonists.
  • Mifomelatide (TCMCB07 / B07) A dual MC3R/MC4R antagonist therapeutic peptide being evaluated in Phase 2 clinical trials (Paradox trial, NCT06937177) to prevent and treat cancer cachexia in patients with advanced cancers. It targets the central melanocortin system to prevent unintentional weight loss and preserve muscle and fat mass during chemotherapy.
  • MC4R-Selective Agonists (pipeline program) First-in-class MC4R-selective agonist candidates in preclinical development with potential to address multiple metabolic indications including type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), opioid use disorder, sarcopenia, polycystic ovary syndrome (PCOS), muscle retention adjuvant, and menopausal weight maintenance.
  • MC3R-Selective Agonists (pipeline program) First-in-class MC3R-selective agonist candidates in preclinical development targeting additional metabolic disorders with significant unmet medical needs.

Quantifiable outcome

  • 11.7% body weight loss at 13 weeks in diet-induced obese nonhuman primates treated with 710GO
  • +5 more outcomes

Companies that use Kalohexis

Customer profile

Segments2 records

Ideal customer profiles3 records

Kalohexis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Kalohexis partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • WuXi ClinicalcoreStrategic or Co-development Partner · 30 April 2025WuXi Clinical is partnered with Kalohexis (formerly Endevica Bio) for the Phase 2 clinical trial of mifomelatide (TCMCB07) for cancer cachexia. The trial includes 20 sites and 100 patients diagnosed with stage 4 metastatic colorectal cancer. WuXi Clinical provides clinical research services supporting the trial administration and patient enrollment.
  • Endevica BiocoreStrategic or Co-development Partner · 21 April 2025Endevica Bio spun out Kalohexis in March 2026 to advance clinical development of the melanocortin-based therapeutic pipeline. Endevica Bio, a world leader in discovery of first-in-class synthetic peptidomimetics, had developed the core technology and pipeline assets over more than a decade. Kalohexis now administers ongoing clinical trials including the Phase 2 Paradox trial (NCT06937177) initiated by Endevica Bio. Kalohexis leadership includes Endevica Bio executives.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Kalohexis competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Kalohexis social profiles

Digital presence

Kalohexis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kalohexis leadership team

Management profile

Number of profiles

Profiles6 records

Kalohexis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kalohexis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kalohexis

What does Kalohexis do?

Kalohexis is a clinical-stage biotechnology company developing a proprietary pipeline of therapeutic peptides that target the central melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) to treat metabolic disorders. Its lead clinical assets are 710GO, an oral dual MC3R/MC4R agonist for general obesity currently in Phase 1 testing in Australia, and mifomelatide (TCMCB07), a dual MC3R/MC4R antagonist for cancer cachexia currently in Phase 2 (Paradox trial, NCT06937177) for advanced colorectal cancer. The pipeline also includes preclinical MC4R-selective and MC3R-selective agonist programs targeting additional metabolic indications such as type 2 diabetes, MASH, opioid use disorder, sarcopenia, and polycystic ovary syndrome.

Is Kalohexis a public or private company?

Kalohexis is a private company. It is classified as corporate owned and is currently operating.

When was Kalohexis founded?

Kalohexis was founded in 2026. It employs 1 to 10 people.

Where is Kalohexis based?

Kalohexis is headquartered in Northbrook, United States, in the North America region.

How does Kalohexis make money?

One revenue line is on record: pharmaceutical Development.

Does Kalohexis have an API?

No public API is recorded for Kalohexis.

What industry is Kalohexis in?

Kalohexis's product category is Metabolic Disease Peptide Therapeutics. Its primary akta.pro industry code is HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies, with a secondary code of HLAIACAE, Gastroenterology Specialty Pharmaceuticals.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireKalohexis Appoints Thomas Forest Farb-Horch to Board of DirectorsKalohexis appointed Thomas Forest Farb-Horch to its Board of Directors, where he will chair the Audit Committee. He brings over three decades of experience in life sciences and AI, including roles at Indevus, Interneuron, and Cytyc. The appointment aims to support Kalohexis's clinical programs and growth.MorningstarKalohexis Appoints Garry Menzel, Ph.D., to Board of DirectorsKalohexis appointed Garry Menzel, Ph.D., to its Board of Directors on Sept. 1, 2026. Menzel brings over 30 years of healthcare executive experience, including leading TCR² Therapeutics and serving as an operating partner at GHO Capital. He will support Kalohexis's melanocortin-based pipeline for obesity and cancer cachexia.pharmaphorumObesity biotech Kalohexis files confidential IPOObesity drug developer Kalohexis has filed a confidential IPO with the SEC, shortly after spinning out from Endevica Bio in March. The company is advancing its lead candidate 710GO, which showed significant weight reduction in preclinical trials without certain side effects associated with existing GLP-1 therapies like Wegovy and Zepbound.PR NewswireKalohexis Appoints Life Sciences Leader, Jeffrey Sherman, MD, to Board of DirectorsKalohexis appointed Jeffrey Sherman, former CMO of Horizon Therapeutics, to its board of directors. Sherman brings over 35 years of R&D and regulatory experience, including roles at Takeda, NeoPharm, and Searle. He will support Kalohexis's melanocortin-based pipeline for obesity and cancer cachexia.PR NewswireKalohexis Presents Data Demonstrating Dual MC3R/MC4R Activation Drives Weight Loss, Limits Rebound, and Preserves Lean Mass in Obese Nonhuman Primates at ICO 2026Kalohexis will present data on its oral dual MC3R/MC4R agonist 710GO at ICO 2026, showing weight loss, limited rebound, and preserved lean mass in obese nonhuman primates. The data, previously shown at ENDO 2026, support 710GO's Phase 1 trial for general obesity. The company also has mifomelatide for cancer cachexia.BioWorldFinancings for July 8, 2026On July 8, 2026, biopharma and med-tech companies Fore, Healome, Kalohexis, and Semnur raised money in public or private financings. The companies are listed in a BioWorld brief on financings for that date.Investing.comKalohexis files confidential IPO draft registration with SEC By Investing.comKalohexis, Inc., a clinical-stage biotechnology company developing treatments targeting the melanocortin system for metabolic diseases such as obesity and cancer cachexia, has submitted a confidential draft registration statement on Form S-1 to the Securities and Exchange Commission for a proposed initial public offering of its common stock. The company has not yet determined the number of shares to be offered or the price range for the proposed offering. The IPO is expected to proceed after the SEC completes its review, subject to market and other conditions.ReutersObesity biotech Kalohexis confidentially files to go public in USObesity-focused biotechnology company Kalohexis confidentially filed to go public in the U.S., contributing to a rebound in initial public offering activity. The company, which spun out of Endevica Bio in March, is developing peptide-based treatments for metabolic disorders and cachexia.PR NewswireKalohexis Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public OfferingKalohexis, a clinical-stage biotechnology company, confidentially submitted a draft S-1 to the SEC for a proposed initial public offering of its common stock. The number of shares and price range have not been determined, and the offering is expected after SEC review, subject to market conditions.BioWorldKalohexis’ dual agonist achieves sustained fat loss with minimal reboundKalohexis Inc. presented preclinical efficacy data on 710GO, an oral dual MC3R/MC4R agonist, in obese nonhuman primates at the Endocrine Society meeting in Chicago. The data showed sustained fat loss with minimal rebound.